Search clinical trials for: BMS-986141

Total 1992 results

Bristol-Myers Squibb

Withdrawn

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Healthy
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Ischemic Stroke

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

Coronary Artery Disease | Healthy Participants

United Kingdom
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Thrombosis

United States, Japan
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

N/A - Healthy Subjects

United States
University of Alabama at Birmingham

Completed

Real-World Evaluation of the Effect of Jublia on Nail Polish

Evaluation of Jublia on Nail Polish With Healthy Toenails

United States
Bristol-Myers Squibb

Completed

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Thrombosis

United States
Johns Hopkins University
National Institute of Mental Health (NIMH)

Recruiting

Improving Screening and Follow Up for Suicidal Ideation and Behaviors Among Latinx Youth in Primary Care (PALOMA)

Suicidal Ideation

United States
Wroclaw Medical University

Completed

Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome

Burning Mouth Syndrome | Glossodynia

Poland
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Atherothrombotic Diseases
Centre Hospitalier le Mans

Recruiting

Validation of a Predictive Rule for the Diagnosis of Viral Meningitis in Adult Emergency Departments (Adult-BMS)

Meningitis

France
Bristol-Myers Squibb

Completed

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Heart Failure

United States
Samsung Medical Center

Completed

Bare Metal Stents and Drug Eluting Stents in Patients Who Underwent Blood Transfusion (TFPCI2)

Percutaneous Coronary Intervention | Erythrocyte Transfusion | Revascularization

Korea, Republic of
Bristol-Myers Squibb

Completed

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Azienda Ospedaliera San Camillo Forlanini

Completed

Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions (CREDENTIAL)

Endothelial Dysfunction

Italy
The University of Hong Kong
Caritas Medical Centre, Hong Kong

Not yet recruiting

A Brief Body-mind-spirit Intervention to Promote Positive Emotions

Stress | Emotions
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Neuroendocrine Tumors | Carcinoid Tumor

United States
London School of Hygiene and Tropical Medicine
Camden Primary Care Trust, London; London Borough of Camden Housing and Adult...

Completed

Health and Environmental Effects of Boiler Management Systems in Social Housing

Hot Water Burns (Scalds)

United Kingdom
Academisch Medisch Centrum - Universiteit van Amsterdam...

Not yet recruiting

Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success? (OUTBACK)

Osteochondral Lesion of Talus
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors (RELATIVITY 059)

Advanced Solid Tumors

China
Bristol-Myers Squibb

Completed

A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants

Healthy Volunteers

United Kingdom
Bluedrop Medical Limited

Recruiting

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration (MASTER)

Diabetic Foot

United States
Bristol-Myers Squibb

Completed

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Cancer

United States, France
Celgene

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Norway, United States, Spain, United Kingdom, Canada
Bristol-Myers Squibb

Completed

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Dermatitis, Atopic

Germany, Australia, Poland, Canada, Austria, United States, Spain
University of California, San Francisco

Terminated

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

Temporomandibular Joint Dysfunction Syndrome | Burning Mouth Syndrome

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Healthy Male Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Gastric Adenocarcinoma | Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma | Esophagus Cancer | Gastroesophageal Junction Squamous Cell Carcinoma

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Taiwan, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Peru, Poland, Portugal, Spain, Switzerla... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
InspireMD

Withdrawn

OCT Study of the MGuard Prime Stent in Patients With Heart Attacks (MASTER-OCT)

ST Segment Elevated Myocardial Infarction

United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

Lupus

United States, Argentina, Germany, Mexico, Poland, Romania, Bulgaria, Spain
Hoffmann-La Roche

Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Healthy Adults

United States
Bristol-Myers Squibb

Terminated

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer

Australia, United States, Canada
Bristol-Myers Squibb

Terminated

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

Hypertension

Sweden, United States, Puerto Rico, Hungary, Colombia
Bristol-Myers Squibb

Terminated

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Depression

France, South Africa, Sweden, United States, Australia, Italy, Argentina, Austria, Spain, Finland, India, Puerto Rico
Bristol-Myers Squibb

Completed

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Alzheimer's Disease

France, Sweden, United States, Germany, Canada
Yale University
National Cancer Institute (NCI)

Terminated

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

Cancer Head Neck | Metastatic Cancer | Metastatic Lung Cancer

United States
Bristol-Myers Squibb

Terminated

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Healthy Participants | Primary Sjögren's Syndrome

Germany, United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Healthy Participants

United States

Search clinical trials for: BMS-986141

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations